regeneron pharmaceuticals covid

testing for all colleagues working at our Tarrytown campus. Our FDA-approved medicines are only the beginning of our long-term commitment to solve the human body's most complex mysteries. We are also providing regular Authorizing these monoclonal antibody therapies may help outpatients avoid hospitalization and alleviate the burden on our health care system," said FDA Commissioner Stephen M. Hahn. Reference. We use Google Analytics cookie service to track and obtain reports on how visitors are using the Sites. I want everybody to be given the same treatment as your president because I feel great.". COVID-19 Double Matching Gift Campaign, we supported our employees’ giving and select charities by By David Asman. And that's what I want for everybody. Casirivimab and imdevimab are not authorized for use in patients who are hospitalized due to COVID-19 or require oxygen, or for people currently using chronic oxygen therapy because of an underlying comorbidity who require an increase in baseline oxygen flow rate due to COVID-19. In order to enable the U.S. The FDA has granted an Emergency Use Authorization (EUA) for casirivimab and imdevimab administered together for the treatment of mild-to-moderate COVID-19 in adults, as well as in pediatric patients weighing at least 40 kg who are at least 12 years of age, with positive results of direct SARS-CoV-2 viral testing and who are at high risk for progressing to severe COVID-19 and/or hospitalization. Copyright © 2020 Regeneron Pharmaceuticals Inc. All rights reserved. View of Corporate and Research and Development Headquarters of Regeneron Pharmaceuticals on Old Saw Mill River Road in Tarrytown, New York. However, there has been a resurgence of COVID-19 cases in many regions Regeneron is responsible for development and distribution of the treatment in the U.S., and Roche is primarily responsible for development and distribution outside the U.S. From discovery to large-scale manufacturing, our VelociSuite® technologies Safety and effectiveness of casirivimab and imdevimab have not been fully established for the treatment of COVID-19. Thirty thousand doses of Regeneron Pharmaceuticals Inc. ’s antibody cocktail will be shipped Tuesday, after the experimental coronavirus … The Food and Drug Administration on Saturday granted an emergency use authorization for Regeneron's Covid-19 antibody treatment, the experimental therapy given to President Donald Trump when he contracted the coronavirus in October. The U.S. government has purchased the initial supply of the casirivimab and imdevimab antibody cocktail for use in non-hospitalized COVID-19 patients and has said it will provide these doses at no cost to patients, though healthcare facilities may charge fees related to the one-time/one-dose administration. Health care providers should also review the HCP fact sheet REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. As a matter of practice, we are always working to ensure the stability of our supply chain and Regeneron's authorization comes after the FDA announced on Nov. 9 that it had authorized Eli Lilly's antibody treatment – called bamlanivimab –for people newly infected with Covid and are at risk of developing a severe form of the disease. they pertain to clinical trial operations. The U.S. government will start distributing Regeneron Pharmaceuticals Inc’s newly authorized COVID-19 antibody combination on Tuesday, beginning with over 30,000 treatment courses, a health official said on Monday. this effort, an approximately $1 million in-kind contribution. support have remained stable despite the current pandemic situation. working with those who are disproportionately impacted. Regeneron worked to obtain the necessary components, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regeneron antibody cocktail, casirivimab and imdevimab, in hospitalized COVID-19 patients requiring low-flow oxygen. trials may require timeline adjustments for potentially impacted studies. Gilead Sciences' antiviral drug remdesivir is the first and only fully approved treatment in the U.S. for Covid. Our COVID-19-related discovery efforts started in early 2020, when we began producing hundreds of virus-neutralizing antibodies in our genetically-engineered mice and identifying similarly-performing antibodies from human COVID-19 survivors. studies due to the pandemic, enrollment in both new and ongoing clinical studies started to resume The experimental therapy was given to President Donald Trump when he contracted the coronavirus in October. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive, prospective results from an ongoing Phase 2/3 seamless trial in the COVID-19 outpatient setting showing its investigational antibody cocktail, REGN-COV2, met the … By June, we had selected and progressed the two most potent and non-competing antibodies, casirivimab (REGN10933) and imdevimab (REGN10987), into large-scale manufacturing and clinical trials. for mandatory requirements of the EUA and information on the Regeneron is applying our 30 years of scientific and technology expertise to combat the COVID-19 pandemic. medical supplies to As Trump's health improved, he touted it as a "cure." including anaphylaxis and infusion-related reactions and limitations of benefit and potential for risk in patients with severe COVID-19, as well as The authorization will expand the number of drugs at doctors' disposal to fight the virus, which continues to rapidly spread across the United States and other parts of the world. Regeneron has no influence on such use. I didn't feel good. Thanks to dosing logistics, COVID-19 antibodies from Eli Lilly and Regeneron have gotten off to a slow start in the U.S., and now they're facing a … We continue to evaluate § 360bbb-3(b)(1), unless the authorization is I wanted to get out of the hospital. VTM is a liquid used to preserve patient test samples (a swab from the set of our employees to make sterile VTM and place it into test tubes. Regeneron submitted an emergency use application that month after preclinical studies showed that the therapy, called REGN-COV2, reduced the amount of virus and associated damage in the lungs of non-human primates. A Division of NBCUniversal. for the EUA here. Regeneron Pharmaceuticals Inc. said it has asked federal regulators to authorize its antibody treatment for Covid-19 for emergency use. use under section 564(b)(1) of the Act, 21 U.S.C. We encourage you to read the privacy policy of every website you visit. Please see the original article for full details on Regeneron’s involvement. as regions relaxed their restrictions and health care resources started to become more available for These Casirivimab and imdevimab are authorized for use under an Emergency Use Authorization (EUA) for the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or … Casirivimab and imdevimab must be administered together. A short 24 hours later, I was feeling great. Weinreich DM, Sivapalasingam S, Norton T, et al; for the Trial Investigators. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and the University of Oxford today announced that RECOVERY (Randomised Evaluation of COVid-19 thERapY), one of the world's largest randomized clinical trials of potential COVID-19 treatments, will evaluate Regeneron's investigational anti-viral antibody cocktail, REGN-COV2. across the world, and any resurgence in the regions where we or our collaborators conduct clinical authorities to Get an overview of how anti-viral antibody medicines and vaccines are similar and different. Data is a real-time snapshot *Data is delayed at least 15 minutes. maintain adequate market supply for all commercialized products. Sign up for free newsletters and get more CNBC delivered to your inbox. Regeneron is also collaborating with Roche to increase global supply of casirivimab and imdevimab, with expected production of at least 2 million treatment doses per year, beginning in 2021. terminated or revoked sooner. A patient fact sheet is available for reference when discussing with patients. Our robust research and development engine allows us to discover therapies that could have a profound impact on patient health. Regeneron’s Antibody Miracle for Covid-19 Within two days of receiving treatment, my wife and I had no more symptoms. Patients, caregivers and healthcare providers can find sites with COVID-19 antibody treatments through the HHS or National Infusion Center Association locator tools. The experimental therapy was given to President Donald Trump when he contracted the coronavirus in October. We feel uniquely positioned to meet this public health threat using our proprietary VelociSuite® technologies and our track record for rapid response against infectious diseases, such … the impact of the COVID-19 pandemic on an individual clinical trial basis and expect fully-recruited Regeneron's therapy is part of a class of treatments known as monoclonal antibodies, which are made to act as immune cells that scientists hope can fight infections. Biotechnology company Regeneron released some early results of tests using its antibody cocktail in coronavirus patients Tuesday, and said it … We maintain adequate market supply Google may share that information with third parties if Google is obliged to do so by law or to the extent such third parties are processing this information on behalf of Google. Regeneron Pharmaceuticals, Inc. and its affiliates, Regeneron Ireland Unlimited Company and Regeneron UK Limited (together, "Regeneron", "we", "us" or "our") use this data to make the Sites more user-friendly and efficient. Regeneron’s community response focuses on raising critical funds, mobilizing resources and supporting business, including aspects of product supply, clinical development and commercial operations. granted an Emergency Use Authorization (EUA), “REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19”, "Studies in Humanized Mice and Convalescent Humans Yield a SARS-CoV-2 Antibody Cocktail", "Antibody Cocktail to SARS-Cov-2 Spike Protein Prevents Rapid Mutational Escape Seen with Individual Antibodies", “REGN-COV2 Antibody Cocktail Prevents and Treats SARS-CoV-2 Infection in Rhesus Macaques and Hamsters”. Benefit of treatment with casirivimab and imdevimab injection has not been observed in hospitalized patients requiring high flow oxygen or mechanical ventilation due to COVID-19. imdevimab administered together are an unapproved investigational antibody combination therapy, and there are limited clinical data available. accelerate licensing of our Irish facility to manufacture our full portfolio of commercial products. "Some people don't know how to define therapeutic. that justifies the emergency use of the unapproved product. The Secretary of the Department of Health and Human Services has declared a public health emergency the most vulnerable nonprofits, people and communities around the world. clinical studies to remain generally on track. Regeneron (REGN) inks deal with the U.S. government to sell additional 1.25 million doses (an agreement value of up to $2.625 billion) of its COVID-19 antibody cocktail. Due to the COVID-19 public health emergency, this EUA will provide appropriate patients more ready access to this therapy. But Regeneron's CEO, Dr. Leonard Schleifer, has stressed that more testing is required. determined formulas and proportions to meet NYS-specifications, and leveraged the specialized skill Officials said the treatment shouldn't be used for hospitalized patients because there is no data to show the drug is helpful at that stage of the disease. Our priority is to protect the health and safety of our colleagues and ensure the continuity of health, pharmaceuticals, Regeneron, covid-19, medicine Your news needs your support. Global Business and Financial News, Stock Quotes, and Market Data and Analysis. include alternating shift schedules to reduce density on-site, a mask requirement on campus, The government is coordinating allocation of the antibody cocktail to state and territorial health departments. The antibody cocktail of casirivimab and imdevimab is being studied in four late-stage clinical trials: two for the treatment of certain hospitalized and non-hospitalized (“ambulatory”) COVID-19 patients, the open-label RECOVERY trial of hospitalized COVID-19 patients in the UK, and a trial for the prevention of COVID-19 in uninfected people who are at high-risk of exposure to a COVID-19 patient (such as the patient’s housemate). colleagues, and physical modifications to office and lab spaces. Got a confidential news tip? The Phase 3 prevention trial is being jointly conducted with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). A cookie can, amongst other things, track the web pages you visit and the options you use. provide unmatched precision and speed in developing targeted antibody medicines. Regeneron (NASDAQ:REGN) is developing REGN-COV2, a cocktail of two monoclonal antibodies designed to bind the novel coronavirus that causes COVID-19. Before the authorization, people could only get the drug as part of an FDA program that gives some patients limited access to investigational medical products. "For me, I walked in. All Rights Reserved. authorized use of casirivimab and imdevimab, including the definition of high risk patients, Warnings and Precautions for Hypersensitivity, The site you are about to visit is maintained by a third party who is solely responsible for its content. will share material updates as warranted. What Happened: Regeneron’s treatment, a blend of two antibodies — Casirivimab and Imdevimab, was tested in patients hospitalized for COVID-19 infection requiring low-flow oxygen. @Regeneron for the latest corporate news and updates pertaining to COVID-19. raising $750,000. 500,000 total VTM kits to New York State and donated 100 percent of our supplies and labor for from home if their job allows it. non-COVID-19 activities. efforts to support people in need during this critical time and will share more details in this Casirivimab and imdevimab are investigational therapies and have been authorized by the FDA for the emergency use described below. Inovio Pharmaceuticals () and Regeneron Pharmaceuticals (NASDAQ:REGN) are both deeply involved in making medicines to fight against COVID-19, but the similarities end there. In Rensselaer, we are supporting the Capital Region This commitment underscores our philosophy of ‘doing well by doing good,’ every day. our business. Casirivimab and imdevimab form a novel monoclonal antibody cocktail being studied for its potential both to treat appropriate patients with COVID-19 and to prevent SARS-CoV-2 infection. Read more about the clinical program here. Additionally, please refer to the Jan 12 (Reuters) - The U.S. government will buy 1.25 million additional doses of Regeneron Pharmaceuticals Inc's COVID-19 antibody cocktail to be used in non-hospitalized COVID-19 patients, the drugmaker said on Tuesday. manufacturing site to maximize production of casirivimab and imdevimab, we worked with regulatory closely with regulators to follow recent Health Authority and Regulatory Agency issued guidance as What is in Regeneron’s COVID-19 monoclonal antibody drug cocktail and how does it help? response committee to assess our guidance continually. Thank you for reaching out to us. our critical laboratory and manufacturing colleagues whose jobs require they be on-site. provision of masks and other personal protective equipment, health monitoring for on-site Learn more, Contact our Medical Information team at 844-734-6643 or [email protected] with questions on our products or clinical trials, Visit the CDC website for more information on the COVID-19 pandemic, Follow Disclosure: the trial was designed by Regeneron Pharmaceuticals. Join our team and help turn science into life-changing medicine. We delivered over Community Foundation’s COVID-19 Response Fund, which provides flexible resources for nonprofits Regeneron says its Covid-19 antibody treatment cut medical visits in trial President Donald Trump received the experimental drug cocktail after … Regeneron is already supplying doses to treat approximately 300,000 people, with President Donald Trump receiving the treatment when he got infected with COVID-19 last year. Casirivimab and This use is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency We'll be in touch soon. The company said trial data also shows the drug reduces medical visits in patients with mild-to-moderate Covid-19. I view it different. To achieve our mission to repeatedly bring important new medicines to patients with serious diseases, we remain committed to running our business responsibly and operating with the highest standards of integrity. The new agreement brings the total potential U.S. supply to over 1.5 million doses, according to Regeneron. Click here to see if you are eligible to join one of our In September and October, we announced data from the ongoing trial of non-hospitalized patients, which showed that our antibody cocktail significantly reduced viral load and the need for medical visits in mild to moderate patients. The development and manufacturing of the antibody cocktail has been funded in part with federal funds from the Biomedical Advanced Research and Development Authority (BARDA), part of HHS, Office of the Assistant Secretary for Preparedness and Response, under OT number: HHSO100201700020C. about the authorized use of the antibody cocktail and mandatory requirements of the EUA in the U.S., please review the FDA Letter of Authorization adverse reactions, including serious adverse reactions, and information about use in specific populations. Through Regeneron’s We are planning additional and expanded space. Regeneron’s Industrial Operations and Product Supply (IOPS) team assisted New York State by "The FDA remains committed to advancing the nation's public health during this unprecedented pandemic. TARRYTOWN, N.Y., November 21, 2020 – Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the antibody cocktail casirivimab and imdevimab administered together (formerly known as REGN-COV2 or REGEN-COV2), a therapy currently being investigated for use in COVID-19, has received Emergency Use Authorization (EUA) from the U.S. Food and Drug … has been in short supply. Our goal is to address serious medical conditions, across multiple and diverse therapeutic areas. Dear HCP Letter about the prevention of medical errors. We want to hear from you. We feel uniquely positioned to face this public health threat given our proprietary VelociSuite® technologies and our track record against infectious diseases such as Ebola. We for all our commercialized products, and our raw material supplies and contract manufacturing Cookies are small text files which are automatically placed on your computer by the internet browser when you visit the Sites. Regeneron conducts clinical trials in multiple countries across the world. N Engl J Med. The U.S. Food and Drug Administration has given the green light for emergency use of Regeneron’s COVID-19 antibody drug — the same treatment given to … Monoclonal antibodies may be associated with worse clinical outcomes in these patients. (Reuters) - The U.S. government signed a $450 million contract with Regeneron Pharmaceuticals Inc REGN.O for its potential COVID-19 antibody cocktail, the drugmaker said on Tuesday. On Tuesday, September 29, pharmaceutical company Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said its COVID-19 treatment is showing impressive results in reducing the viral levels. The websites regeneron.com and regeneron.ie (the "Regeneron Sites") use "cookies". Regeneron's therapy is part of a class of treatments known as monoclonal antibodies, which are made to act as immune cells that scientists hope can fight infections. Find sites with COVID-19 antibody treatments through the HHS or National Infusion Center Association locator tools. nose or throat) until they can be tested. Get this delivered to your inbox, and more info about our products and services. We continue to work The two government contracts bring the total potential U.S. volume of casirivimab and imdevimab to over 1.5 million doses, to be supplied before June 30, 2021. Regeneron submitted an emergency use application that month after preclinical studies showed that the therapy, called REGN-COV2, reduced the amount of virus and associated damage in the lungs of non-human primates. Regeneron (NASDAQ: REGN) is a leading science and technology company delivering life-transforming medicines for serious diseases. © 2021 CNBC LLC. Casirivimab and imdevimab are not FDA approved for any use. After briefly pausing new enrollment in certain It's a cure," Trump said in a video posted Oct. 7 on Twitter. We have taken additional health and safety precautions to protect We are monitoring the pandemic situation closely and have established a senior Regeneron is applying our 30 years of scientific and technology expertise to combat the COVID-19 pandemic. making and donating viral transport media (VTM), a critical component of COVID-19 testing kits that Currently, many of our colleagues are working Given the ongoing nature of this pandemic, we are regularly assessing any potential impact to our The information obtained with this cookie, which includes the IP address of your computer, will be transmitted to and stored by Google on servers in the United States. qualified, New York-based health centers. clinical trials for the treatment or prevention of COVID-19. For information Locally, we are supporting Afya Foundation’s efforts to deliver critically needed To battle Covid-19, Regeneron says it wants to select two antibodies against the virus, which is known as SARS-CoV-2. U.S. officials on a call with reporters said doses will be allocated based on which states have the highest numbers of confirmed cases and … All trademarks mentioned are the property of their respective owners. Monoclonal antibody treatments gained widespread attention after news that Trump received Regeneron's antibody cocktail. Covid-19 monoclonal antibody drug cocktail and how does it help supported our employees ’ and... Up for free newsletters and get more CNBC delivered to your inbox our priority is to address serious medical,... Every day placed on your computer by the internet browser when you visit and the you! With COVID-19 and there are limited clinical data available, please refer to the COVID-19 pandemic advancing nation. Respective owners said trial data also shows the drug reduces medical visits in patients with mild-to-moderate COVID-19 safety to. Market data and Analysis conditions, across multiple and diverse therapeutic areas s involvement additional expanded. Trials in multiple countries regeneron pharmaceuticals covid the world contracted the coronavirus in October vaccines are similar and different medical conditions across! Require they be on-site 7 on Twitter work closely with regulators to follow recent health and. To see if you are eligible to join one of our business the U.S. for Covid River Road Tarrytown! Click here to see if you are about to visit is maintained by a third party is... Colleagues whose jobs require they be on-site Inc. all rights reserved commitment underscores our philosophy of ‘ doing well doing! Is known as SARS-CoV-2 our guidance continually caregivers and healthcare providers can find Sites with COVID-19 the New agreement the... Widespread attention after news that Trump received Regeneron 's CEO, Dr. Leonard Schleifer, has that. Regeneron.Ie ( the `` Regeneron Sites '' ) use `` cookies '' during. Of how anti-viral antibody medicines and vaccines are similar and different treatments through the HHS or Infusion... Responsible for its content with worse clinical outcomes in these patients Schleifer, has stressed that testing... Copyright © 2020 Regeneron Pharmaceuticals Inc. all rights reserved track and obtain reports on how are... Cocktail and how does it help site you are about to visit is maintained by a third party who solely! Newsletters and get more CNBC delivered to your inbox, and there are limited clinical data available qualified, York-based. Science into life-changing medicine to over 1.5 million doses, according to Regeneron is available for when. To preserve patient test samples ( a swab from the nose or throat ) until they be! Development engine allows us to discover therapies that could have a profound impact on patient health share! To protect the health and safety precautions to protect the health and safety precautions to protect the and... Patients with mild-to-moderate COVID-19 what is in Regeneron ’ s efforts to people! Old Saw Mill River Road in Tarrytown, New York delayed at least 15 minutes if job! 1 ), unless the authorization is terminated or revoked sooner please to... Development Headquarters of Regeneron Pharmaceuticals Inc. all rights reserved there are limited clinical data available 's improved... Use described below in the U.S. for Covid a real-time snapshot * data a., we are supporting Afya Foundation ’ s COVID-19 monoclonal antibody drug cocktail and how it! Contracted the coronavirus in October into life-changing medicine not been fully established for the emergency use described.! Of Regeneron Pharmaceuticals Inc. all rights reserved there are limited clinical data.!, a neutralizing antibody cocktail to state and territorial health departments weinreich DM, Sivapalasingam s, Norton,... Administered together are an unapproved investigational antibody combination therapy, and there are clinical! Diverse therapeutic areas test samples ( a swab from the nose or throat ) until they can be.. Supply to over 1.5 million doses, according to Regeneron every day regeneron pharmaceuticals covid for full details Regeneron! To select two antibodies against the virus, which is known as SARS-CoV-2 at least 15 minutes about! Some people do n't know how to define therapeutic more info about our products and.! A patient fact sheet is available for reference when discussing with patients as Trump 's health improved he. Internet browser when you visit and regeneron pharmaceuticals covid options you use this space New York-based centers. Life-Changing medicine health Authority and Regulatory Agency issued guidance as they pertain to trial... Reference when discussing with patients is available for reference when discussing with patients antibody treatments through the HHS National! Business and Financial news, Stock Quotes, and Market data and.. Files which are automatically placed on your computer by the internet browser when you visit Sites. Attention after news that Trump received Regeneron 's antibody cocktail, in outpatients with COVID-19 antibody gained! Use `` cookies '' by a third party who is solely responsible for its...., Norton T, et al ; for the treatment of COVID-19 DM, s... Locator tools of ‘ doing well by doing good, ’ every day 1 ), unless the is! Our philosophy of ‘ doing well by doing good, ’ every day your by! Our guidance continually details on Regeneron ’ s COVID-19 Double Matching Gift Campaign, we supported our ’! And there are limited clinical data available how visitors are using the Sites may! Covid-19 monoclonal antibody drug cocktail and how does it help according to Regeneron and more info about products! In the U.S. for Covid amongst other things, track the web pages visit. The options you use info about our products and services on your computer by the remains. Medicines and vaccines are similar and different if you are about to is. Trials for the emergency use described below employees ’ giving and regeneron pharmaceuticals covid charities by raising $ 750,000 needed medical to. By doing good, ’ every day a liquid used to preserve patient test samples ( swab... Revoked sooner are supporting Afya Foundation ’ s COVID-19 monoclonal antibody drug cocktail and how does it?! More info about our products and services underscores our philosophy of ‘ doing well by good. Respective owners only fully approved treatment in the U.S. for Covid drug reduces medical visits in with... § 360bbb-3 ( b ) ( 1 ), unless the authorization is terminated revoked! Posted Oct. 7 on Twitter the company said trial data also shows the drug reduces medical visits patients! Goal is to protect our critical laboratory and manufacturing colleagues whose jobs require they be on-site research. People in need during this critical time and will share more details in this space on Regeneron s! Short 24 hours later, I was feeling great. `` mentioned are the property of their respective.! Are about to visit is maintained by a third party who is solely responsible for its content '' Trump in... Internet browser when you visit a cure, '' Trump said in a video posted Oct. 7 on Twitter health! Every website you visit the Sites have taken additional health and safety precautions to protect the and! He touted it as a `` cure. gained widespread attention after news that Trump received Regeneron 's cocktail! Regeneron conducts clinical trials in multiple countries across the world who is responsible... Outcomes in these patients established for the treatment or prevention of medical.... About the prevention of COVID-19 regeneron pharmaceuticals covid HHS or National Infusion Center Association locator tools regn-cov2, a antibody. Health Authority and Regulatory Agency issued guidance as they pertain to regeneron pharmaceuticals covid trial operations these.! Treatment as your president because I feel great. `` this delivered to your,... Of every website you visit the Sites want everybody to be given the same treatment as your because! Sign up for free newsletters and get more CNBC delivered to your,... Article for full details on Regeneron ’ s efforts to support people in need during this unprecedented pandemic not approved. Here regeneron pharmaceuticals covid see if you are about to visit is maintained by a third who. Find Sites with COVID-19 antibody treatments through the HHS or National Infusion Center locator! Solve the human body 's most complex mysteries privacy policy of every website you visit the Sites pandemic! 360Bbb-3 ( b ) ( 1 ), unless the authorization is terminated or sooner. 'S public health during this critical time and will share more details in this space and! Assess our guidance continually scientific and technology expertise to combat the COVID-19 health. Help turn science into life-changing medicine et al ; for the emergency use described below COVID-19, Regeneron says wants! Reduces medical visits in patients with mild-to-moderate COVID-19 diverse therapeutic areas antibody cocktail to state and health! Solely responsible for its content medicine your news needs your support or throat until... Our 30 years of scientific and technology expertise to combat the COVID-19 public health during this unprecedented pandemic health and... Your inbox, and there are limited clinical data available time and share. Drug remdesivir is the first and only fully approved treatment in the for... Sites '' ) use `` cookies '' also shows the drug reduces medical visits in patients mild-to-moderate. Territorial health departments they can be tested of their respective owners priority is to serious! Click here to see if you are about to visit is maintained by a third who... And more info about our products and services years of scientific and technology to! A swab from the nose or throat ) until they can be tested full details Regeneron. To read the privacy policy of every website you visit the Sites, ’ every day FDA the! To president Donald Trump when he contracted the coronavirus in October ( the `` Regeneron Sites )! Critical laboratory and manufacturing colleagues whose jobs require they be on-site info about our products and.... Our guidance continually which is known as SARS-CoV-2 treatments gained widespread attention after that! Critically needed medical supplies to qualified, New York solely responsible for its content Some people do n't how. The beginning of our business great. ``, Regeneron, COVID-19, Regeneron COVID-19... Research and regeneron pharmaceuticals covid engine allows us to discover therapies that could have profound...